Search Results

Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform.

Multiply Labs and Retro Biosciences announced a first-of-its-kind commercial and supply agreement valued at up to $85 million to automate Retro’s groundbreaking approach.

GenScript Biotech Corporation and Multiply Labs announced a strategic partnership around the automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process.

Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced its upcoming collaboration with Stanford Medicine’s Laboratory for Cell & Gene Medicine (LCGM) to demonstrate the potential of automation technology for cell therapy manufacturing.

Multiply Labs and Fedegari Group Collaborate to Add Sterilization to Automated Cell Therapy Manufacturing for Eliminating Contamination Risks.

Multiply Labs today announced that Cytotherapy, the official journal of the International Society for Cell & Gene Therapy (ISCT), published a peer-reviewed research article focused on the performance of its proof-of-concept robotic system developed alongside a group of leading cell therapy organizations.

Through integration with Multiply Labs’ robotic technology, Thermo Fisher Scientific’s advanced, industry-leading cell therapy instruments, including the Thermo Scientific™ Heracell™ VIOS Automated Access CO 2 Incubator and the Gibco™ Cell Therapy Systems (CTS™) Rotea™ Counterflow Centrifugation System can now be fully automated for cell therapy manufacturing.

Multiply Labs and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, today announced a non-exclusive partnership focused on automating and standardizing the use of cytokines in cell therapy manufacturing.

Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, announced that its proof-of-concept robotic system, developed along with UCSF, Cytiva, Thermo Fisher Scientific and Charles River, has been successfully completed.

WuXi STA, a subsidiary of WuXi AppTec and a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the partnership with Multiply Labs (based in San Francisco, CA, USA), a robotics company that has developed industry-leading automated manufacturing systems to produce individualized drugs.